Immunovaccine Announces Year-End 2017 Financial Results

- March 21st, 2018

Immunovaccine (TSX:IMV) a clinical stage immuno-oncology corporation, today released its financial and operational results for the fiscal year ended December 31, 2017. As quoted in the press release: “2017 was a truly pivotal year for Immunovaccine.  We released our first clinical efficacy results, with the topline data for our lead product candidate, DPX-Survivac, in recurrent …

Immunovaccine (TSX:IMV) a clinical stage immuno-oncology corporation, today released its financial and operational results for the fiscal year ended December 31, 2017.

As quoted in the press release:

“2017 was a truly pivotal year for Immunovaccine.  We released our first clinical efficacy results, with the topline data for our lead product candidate, DPX-Survivac, in recurrent ovarian cancer. This announcement reflects our most significant clinical milestone so far for two major reasons: it supports the potential of the novel anti-cancer activity of DPX-Survivac; and reduces the risk-profile of our future clinical developments, thus providing, we believe, a solid foundation for our ambitious development plan,” said Frederic Ors, Immunovaccine’s Chief Executive Officer.

Click here to read the full press release.

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply